ALung Submits IDE Application to FDA Seeking Approval to Conduct Pivotal Study of the Hemolung RAS

25 April 2017 Recent News

PITTSBURGH (April 25, 2017) – ALung Technologies, Inc., announced today the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking approval to conduct a pivotal clinical study of the Hemolung Respiratory Assist System for the treatment of adults with severe acute exacerbations of chronic obstructive pulmonary disease (read more)

ALung Technologies Forms Trial Steering Committee

15 November 2016 Press Release, Recent News

Renowned physicians will oversee landmark trial of the Hemolung RAS in patients with COPD. PITTSBURGH (November 15, 2016) – ALung Technologies, Inc., a leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the formation of its Trial Steering Committee (TSC) for its upcoming pivotal trial (read more)

Update on the Hemolung FDA Expedited Access Pathway process

14 June 2016 Recent News

In 2015, we announced that the Hemolung RAS had been selected by the FDA for its new Expedited Access Pathway (EAP) program. This new program aims to reduce the time and cost of market approval for breakthrough medical technologies aimed at addressing significant unmet clinical needs. The program promises to help accomplish this through things (read more)

New study shows promise of ALung’s Hemolung technology to help protect the injured lung

Study results published in the journal Critical Care show that the Hemolung RAS can safely facilitate an ultra-protective ventilation strategy. PITTSBURGH  (February 15, 2016) – ALung Technologies, Inc., a leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the publication of new results from an (read more)

The use of extracorporeal carbon dioxide removal to avoid intubation in patients failing non-invasive ventilation – a cost analysis

25 November 2015 Clinical Update, Recent News

  Background To evaluate the economic implications of the pre-emptive use of extracorporeal carbon dioxide removal (ECCO2R) to avoid invasive mechanical ventilation (IMV) in patients with hypercapnic ventilatory insufficiency failing non-invasive ventilation (NIV). Methods Retrospective ancillary cost analysis of data extracted from a recently published multicentre case–control-study (n = 42) on the use of arterio-venous ECCO2R to (read more)

Early experience of low flow extracorporeal carbon dioxide removal in management of acute hypercapnic respiratory failure

Dr. Ravi Tiruvoipati presented the initial Australian experience with low-flow extracorporeal carbon dioxide removal (Hemolung RAS) at the 2015 Australian and New Zealand Intensive Care Society (ANZICS) meeting. Early experience of low flow extracorporeal carbon dioxide removal in management of acute hypercapnic respiratory failure from alungtech (read more)

Ultra-low tidal volumes and extracorporeal carbon dioxide removal (Hemolung RAS) in ARDS patients. A clinical feasibility study.

Ultra-low tidal volumes and extracorporeal carbon dioxide removal (Hemolung RAS) in ARDS patients. A clinical feasibility study FJ Parrilla*, L Bergesio, H Aguirre-Bermeo, JC Suarez, P López, I Morán, J Mancebo From ESICM LIVES 2015 Berlin, Germany. 3-7 October 2015 Summary: Objective: To evaluate the effect of extracorporeal CO2 removal in ARDS during ultraprotective ventilation in terms of (read more)

Dr. Jeremy Kimmel Featured on Regenerative Medicine Today podcast

11 August 2015 Recent News

Dr. Jeremy Kimmel, ALung’s Director of New Technology, was recently featured as a guest on the “Regenerative Medicine Today” podcast where he discussed Respiratory Dialysis with the Hemolung RAS. Listen to learn: How does Respiratory Dialysis work? What are the benefits of Respiratory Dialysis? The history of ALung Technologies What is the future of extracorporeal (read more)

New Publications Show Promise of Improved Artificial Lung Devices

3 August 2015 Press Release, Recent News

Technology developed at the University of Pittsburgh and licensed by ALung enhances the performance of artificial lung devices, paving the way for the development of less invasive respiratory support systems. Pittsburgh, PA (August 3, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute (read more)

ALung Receives CE Mark for New Hemolung XG4 Cartridge and Catheter Kits

18 June 2015 Press Release, Recent News

The new Hemolung XG4 Cartridge and Catheter Kits further simplify initiation of Respiratory Dialysis®. Pittsburgh, PA (June 18, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today announced that it has received CE mark approval for its next generation Hemolung (read more)